Moderna (MRNA) Retained Earnings: 2017-2025
Historic Retained Earnings for Moderna (MRNA) over the last 7 years, with Sep 2025 value amounting to $8.0 billion.
- Moderna's Retained Earnings fell 27.91% to $8.0 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $8.0 billion, marking a year-over-year decrease of 27.91%. This contributed to the annual value of $10.0 billion for FY2024, which is 26.17% down from last year.
- Moderna's Retained Earnings amounted to $8.0 billion in Q3 2025, which was down 2.42% from $8.2 billion recorded in Q2 2025.
- Over the past 5 years, Moderna's Retained Earnings peaked at $18.4 billion during Q1 2023, and registered a low of -$1.0 billion during Q1 2021.
- In the last 3 years, Moderna's Retained Earnings had a median value of $11.2 billion in 2024 and averaged $12.1 billion.
- In the last 5 years, Moderna's Retained Earnings soared by 1,430.89% in 2022 and then plummeted by 34.47% in 2024.
- Quarterly analysis of 5 years shows Moderna's Retained Earnings stood at $10.0 billion in 2021, then soared by 83.97% to $18.3 billion in 2022, then dropped by 25.73% to $13.6 billion in 2023, then declined by 26.17% to $10.0 billion in 2024, then fell by 27.91% to $8.0 billion in 2025.
- Its Retained Earnings was $8.0 billion in Q3 2025, compared to $8.2 billion in Q2 2025 and $9.1 billion in Q1 2025.